immunotherapy

Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm…

2 months ago

Biotech Valuations Rise as New Clinical Platforms Show Progress

AUSTIN, Texas, Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As advanced biotech programs move closer to commercialization, fair-value…

2 months ago

ModuleMD Showcases Advanced AI-Driven Allergy Solutions at ACAAI 2025

ORLANDO, Fla., Nov. 22, 2025 /PRNewswire/ -- This November at the ACAAI Annual Meeting 2025, one theme dominated the conversations: AI…

2 months ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launchCRANFORD,…

2 months ago

ViVac Appoints Keren Leshem as Chief Executive Officer, Strengthening Leadership to Advance RNA-Lipid Nanoparticle Immunotherapy Platform

JERUSALEM, Nov. 20, 2025 /PRNewswire/ -- ViVac Pharma Ltd., a pioneering synthetic biology company advancing RNA–Lipid Nanoparticle (LNP) immunotherapies, announces the…

2 months ago

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S.…

2 months ago

Syncromune®, Inc. to Present Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at the Society of Urological Oncology 26th Annual Meeting

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company pioneering…

2 months ago

Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture

Independent valuation reflects major advancement of OT-101 and Deciparticle™ nanomedicine platformSAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- via IBN…

2 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiaryPartnership expected to…

2 months ago